Nemaura Medical Inc. (NMRD): history, ownership, mission, how it works & makes money

A Brief History of Nemaura Medical Inc. (NMRD)

Foundation and Early Years

Nemaura Medical Inc. (NMRD) was founded in 2011. The company is based in the United States and focuses on the development of non-invasive and wearable technologies aimed at diabetes management.

Initial Public Offering (IPO)

Nemaura Medical went public on the NASDAQ stock exchange through a reverse merger completed in 2020. The company’s stock began trading on March 30, 2020, under the ticker symbol NMRD.

Technology Development

The company’s flagship product, the SugarBEAT®, is a non-invasive continuous glucose monitoring system designed to provide users with real-time glucose readings. In 2021, Nemaura reported that it had achieved significant milestones in its clinical trials and technology validation.

Regulatory Approvals

In 2021, Nemaura Medical received CE marking for the SugarBEAT device, allowing it to be marketed in the European Economic Area. However, as of October 2023, the device is still awaiting FDA approval in the United States.

Financial Performance

As of Q4 2022, Nemaura Medical reported revenue of approximately $620,000. The company recorded a net loss of around $7.4 million for the same quarter, reflecting ongoing investments in R&D and marketing efforts.

Recent Developments

In 2023, Nemaura Medical announced partnerships with multiple healthcare providers to expand its product reach. The company also launched a subscription model for users, aiming to enhance consumer access to its glucose monitoring technology. The subscription plan is priced at $99 per month, which includes the device and ongoing support.

Stock Performance

As of October 2023, the stock price of Nemaura Medical (NMRD) was approximately $2.50. The company has experienced fluctuations in its stock value since its IPO, with a high of $6.00 shortly after going public.

Market Outlook

Nemaura Medical continues to be positioned in the growing diabetes management market, which is expected to reach a value of $25 billion by 2025. The demand for non-invasive monitoring technologies is anticipated to drive growth, particularly as health awareness and chronic disease prevalence increase globally.

Conclusion of Historical Overview

The company’s journey reflects both the challenges and opportunities present in the medical technology sector. Nemaura Medical’s commitment to innovation and patient-centered solutions marks it as a player to watch in the coming years.

A Who Owns Nemaura Medical Inc. (NMRD)

Shareholder Breakdown

The ownership of Nemaura Medical Inc. (NMRD) can be broken down into various categories of shareholders, including institutional investors, retail investors, and insiders. As of the latest report available, the following statistics summarize the shareholder distribution:

Major Institutional Holders

There are notable institutional investors in Nemaura Medical Inc., which significantly influence the stock's performance and stability. The following table lists the major institutional shareholders:

Insider Ownership

The insider ownership can greatly affect the direction of the company. The following details the key insiders and their respective ownership percentages:

Market Capitalization

The market capitalization of Nemaura Medical Inc. is a crucial factor as it reflects the company's overall value in the stock market:

• Current Stock Price: $2.50
• Total Shares Outstanding: 15,000,000
• Market Capitalization: $37.5 million

Recent Stock Performance

As of the latest trading session, Nemaura Medical Inc. has experienced the following performance metrics:

• 52-Week High: $4.00
• 52-Week Low: $1.50
• Year-to-Date (YTD) Performance: -20%

Conclusion on Ownership Dynamics

The ownership structure of Nemaura Medical Inc. provides insight into the governance and potential future direction of the company, with institutional investors playing a significant role in the stock's performance. The engagement of insiders also contributes to maintaining shareholder confidence.

Nemaura Medical Inc. (NMRD) Mission Statement

Corporate Overview

Nemaura Medical Inc. (NMRD) is a pioneering medical technology company dedicated to improving the quality of life for patients with chronic conditions, particularly diabetes. The mission statement encapsulates the company’s commitment to innovation in non-invasive glucose monitoring and other related healthcare solutions.

Mission Statement

The mission of Nemaura Medical is to enhance patient outcomes through innovative, cost-effective, and user-friendly medical technologies that empower patients to take control of their health.

Core Values

• Innovation
• Patient-Centric Care
• Integrity
• Sustainability
• Collaboration

Strategic Goals

Nemaura Medical aims to achieve specific strategic goals aligned with its mission:

• Implement cutting-edge non-invasive technology into diabetes care.
• Expand market reach through partnerships and collaborations.
• Enhance product accessibility and affordability for patients.
• Advance research and development for further innovations.

Recent Financial Data

As of October 2023, Nemaura Medical’s financial performance includes:

Product Portfolio

Nemaura Medical is focused on developing the following innovative products:

• SugarBEAT®: A non-invasive continuous glucose monitor.
• Wearable Health Technology: Devices designed to track various health parameters.
• Diabetes Management Solutions: Comprehensive tools for managing diabetes effectively.

Market Position

Nemaura Medical is positioned within the rapidly growing digital health market, which is projected to reach:

Research and Development

Nemaura Medical dedicates a significant portion of its resources to R&D:

• R&D Investment (Last Fiscal Year): $1 million
• Number of Patents Filed: 16 patents related to non-invasive health monitoring
• Collaboration with Universities and Research Institutes: 5 active partnerships

Future Outlook

Looking ahead, Nemaura Medical has set ambitious benchmarks for growth and innovation:

• Expand product lines to include additional chronic disease management tools.
• Enhance distribution channels to increase market penetration.
• Invest in securing regulatory approvals for new technologies.
• Build strategic alliances to bolster technological advancements.

How Nemaura Medical Inc. (NMRD) Works

Company Overview

Nemaura Medical Inc. is a pioneering company specializing in non-invasive continuous glucose monitoring technology. Their primary product, the sugarBEAT® device, is designed for diabetics and pre-diabetics to monitor glucose levels without the need for traditional fingersticks. As of October 2023, Nemaura Medical operates on a business model that prioritizes innovation and patient-centric solutions.

Business Model

The company employs a direct-to-consumer approach coupled with partnerships in distribution. Its revenue streams include:

• Product sales of sugarBEAT® devices.
• Subscription fees for continuous monitoring services.
• Partnership agreements with healthcare providers and pharmacies.

Financial Performance

As of the latest financial report for Q2 2023, Nemaura Medical reported:

Research and Development

Nemaura places a strong emphasis on research and development, with expenditures in 2022 totaling approximately $1.5 million. The company focuses on advancing its existing products and developing new technologies, including:

• Enhanced sensors for improved accuracy.
• Integration with mobile health applications.

Market Position and Competition

The glucose monitoring market is highly competitive, with key players including:

• Abbott Laboratories (FreeStyle Libre)
• Dexcom (Dexcom G6)
• Medtronic (Guardian Connect)

Nemaura Medical differentiates itself through unique technology and a strong commitment to non-invasive monitoring solutions.

Regulatory Status

Nemaura Medical has received CE Mark approval for its sugarBEAT® device in Europe. As of October 2023, the company is in the process of seeking FDA approval for entry into the U.S. market, which is projected to expand its customer base significantly.

Business Outlook

The company anticipates growth driven by:

• Rising diabetes prevalence globally.
• Increased demand for non-invasive monitoring solutions.

Forecasts suggest potential revenue growth reaching $5 million by the end of 2024, contingent upon successful regulatory approval and market penetration.

Key Partnerships

Nemaura Medical has established key partnerships to enhance distribution and market reach, including:

• Collaboration with healthcare providers for integrated diabetes management.
• Distribution agreements with pharmaceutical chains.

Conclusion

Nemaura Medical Inc. strives to revolutionize diabetes management through innovative technology. Its focus on non-invasive monitoring provides a competitive edge in a growing market.

How Nemaura Medical Inc. (NMRD) Makes Money

Product Offerings

Nemaura Medical Inc. generates revenue primarily through the sale of its innovative non-invasive glucose monitoring systems, notably the SugarBEAT device. SugarBEAT is designed to help individuals manage diabetes by providing continuous glucose monitoring without the need for finger pricks.

Revenue Streams

• Direct Sales: Revenue from the sale of SugarBEAT devices.
• Subscription Services: Monthly subscription fees for data analytics and access to the companion app.
• Partnerships and Collaborations: Strategic alliances with pharmaceutical companies and healthcare providers.
• Research Grants: Funding from government and private institutions for research and development.

Financial Performance

For the fiscal year ended March 31, 2023, Nemaura Medical reported revenues of approximately $1.54 million, showcasing a growth trajectory as the market for diabetes management expands.

The cost of goods sold (COGS) for the same period was reported at $1.04 million, leading to a gross profit of $0.50 million.

Recent Financial Data

Market Potential

The global glucose monitoring device market is projected to reach $25 billion by 2026, with a CAGR of approximately 6.6% from 2021 to 2026. This provides a substantial opportunity for Nemaura Medical to expand its market share.

Strategic Partnerships

Nemaura has engaged in collaborations with numerous entities to enhance its market reach. Notable partnerships include:

• Verily Life Sciences: Collaboration aimed at integrating health data monitoring.
• Abbott Laboratories: Potential joint ventures for technology sharing.
• Universities and Research Institutions: Research projects funded through grants and partnerships.

Future Projections

Analysts project that Nemaura Medical could achieve annual revenues of over $10 million within the next few years, contingent upon market acceptance and continued product development.